← Back to feed

Coiled Therapeutics plc

COIL · AIM · Health Care · mcap £32m today

All announcements

All RNS · 44 Key events · 36

01 Oct 26

Investor Presentation via Engage Investor

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that the leadership team will host a live interactive presentation...
RNS 9800292 ↗
30 Sep 26

Participation in The Small Cap Showcase

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that members of its executive management team will participate in...
RNS 9797759 ↗
28 Sep 26

Director/PDMR Shareholding Director buys

Coiled Therapeutics (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, advises that Stephen West, Non-Executive Director, has today purchased...
RNS 9794057 ↗
28 Sep 26

Half-year Results

Coiled Therapeutics plc (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces its interim results for the six-month period ended 30 June 2026...
RNS 9792648 ↗
21 Sep 26

Successful Enrolment Completed Across Two Cohorts

Successful Enrolment Completed Across Two Cohorts of New AO-252 Formulation
RNS 9780828 ↗
01 Sep 26

Appointment of Joint Corporate Broker

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, is pleased to announce the appointment of Shore Capital Stockbrokers Limited...
RNS 9747516 ↗
10 Aug 26

Change of Registered Office
RNS 9713525 ↗
03 Aug 26

First Patient Dosed with new Formulation of AO-252

First Patient Dosed with Optimised Lipid-Based Formulation of AO-252
RNS 9699764 ↗
07 Jul 26

Coiled Advances Next-Generation AO-252 Formulation

Lipid-Based Softgel Designed to Optimise Drug Exposure Ahead of Dose Expansion
RNS 9654916 ↗
24 Jun 26

Company Presentation

Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that ahead of its presentation at the Proactive One2One Investor Forum in London at 6pm BST today, the...
RNS 9634787 ↗
24 Jun 26

Result of AGM
RNS 9634628 ↗
24 Jun 26

Appointment of Independent Non-Executive Director

Seasoned biotech and capital markets leader joins the Board
RNS 9633065 ↗
19 Jun 26

Life Sciences Investor Forum

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that the Company's Chairman Sotirios Stergiopoulos will present at the Life Sciences Investor Forum...
RNS 9626578 ↗
18 Jun 26

Proactive One2One Investor Forum

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that it will be presenting at the Proactive One2One Investor Forum (the "Forum") in London on Wednesday...
RNS 9624296 ↗
17 Jun 26

Grant of Share Options

Coiled Therapeutics (AIM:COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces it has granted 6,200,000 share options ("Options") over the Company's ordinary shares of 1 pence each...
RNS 9623015 ↗
17 Jun 26

Establishment of Medical Advisory Board

Leading Oncology Drug Developers Join Coiled Therapeutics Medical Advisory Board to Support AO-252 Clinical Development
RNS 9621955 ↗
08 Jun 26

Appointment of Ozgur Sahin as Scientific Advisor

Appointment of Professor Ozgur Sahin as Scientific Advisor
RNS 9605511 ↗
29 May 26

Issue of Equity
RNS 9590835 ↗
27 May 26

Notice of AGM
RNS 9586492 ↗
19 May 26

Commencement of Trading on US OTCQB Venture Market

Commencement of Trading on US OTCQB Venture Market
RNS 9574288 ↗
07 May 26

Attendance at Endless Frontier Labs 2026

Coiled Therapeutics to Showcase AO-252 at Prestigious Endless Frontier Labs 2026 Event
RNS 9556105 ↗
07 May 26

Appointment of Non-Executive Director

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the appointment of Dr Andrew Dean as Non-Executive Director with immediate effect.
RNS 9555954 ↗
06 May 26

Annual Report & Financial Statements

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, formerly Roquefort Therapeutics plc, announces its audited results for the year ended 31 December 2025.
RNS 9553616 ↗
15 Apr 26

Presentation at 18th Annual World Cancer Congress

Presentation at the 18th Annual World Cancer Congress
RNS 9520480 ↗
08 Apr 26

Clinical Trial Update

Enhanced Efficacy Signal and Strategic Transition to Dose Expansion
RNS 9509151 ↗
01 Apr 26

Total Voting Rights
RNS 9501819 ↗
27 Mar 26

Readmission - Roquefort Therapeutics Plc

NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON THE LONDON STOCK EXCHANGE
RNS 9495585 ↗
27 Mar 26

Admission to Trading and First Day of Dealings
RNS 9495013 ↗
26 Mar 26

Investor Presentation

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence of AO-252 from Coiled Therapeutics,...
RNS 9494242 ↗
26 Mar 26

Result of General Meeting
RNS 9494134 ↗
25 Mar 26

Lyramid SPA & MK Cell License Update

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has agreed to extend the Longstop Dates (defined below) in relation to the binding share purchase agreement ("Lyramid SPA") for the sale of its wholly owned subsidiary...
RNS 9490351 ↗
02 Mar 26

Schedule One - Roquefort Therapeutics PLC

Roquefort will be renamed Coiled Therapeutics plc ("Coiled") upon the completion of the acquisition of the AO-252 Licence from A2A Pharmaceuticals, Inc.
RNS 9453038 ↗
02 Mar 26

Proposed Acquisition and Fundraise of £8.5 million

Proposed Acquisition and Conditional Fundraise of £8.5 million
RNS 9452167 ↗
25 Feb 26

Transaction Update & Notice of Intention to Delist

Transaction Update & Intention to delist from the Main Market
RNS 9445516 ↗
15 Jan 26

Research Note Published

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that a new research note regarding the Company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., as first announced on 8 September...
RNS 9354506 ↗
12 Dec 25

Clinical Trial & License Agreement Update

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that the binding exclusive license agreement with Coiled Therapeutics, Inc.
RNS 9292004 ↗
09 Dec 25

Conversion of CLNs

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that the Company has received notices, in two tranches, to convert a total face value of £80,000 convertible loan notes (the "CLNs") resulting in the issue of 6,282,264 new...
RNS 9283675 ↗
01 Dec 25

Ex-Entitlement Date - Unlisted RNV Shares

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares ("Unlisted...
RNS 9267335 ↗
01 Dec 25

Determination of Record Date and Entitlement

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares ("Unlisted RNV Shares"), the Company confirms...
RNS 9266114 ↗
25 Nov 25

Holding(s) in Company
RNS 9254619 ↗
24 Nov 25

Director/PDMR Shareholding Director buys

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, advises that Dr Darrin Disley, Interim Managing Director, has purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
RNS 9251881 ↗
18 Nov 25

Executed License Agreement & Transaction Update

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce that further to the announcements made on 8 September, 16 October and 3 November 2025, the Company has entered into a binding exclusive license agreement...
RNS 9239867 ↗
03 Nov 25

MK Cell Out-License & Lyramid SPA Update

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd ("Pleiades") in return for up to US$25 million in milestone cash payments...
RNS 9207512 ↗
16 Oct 25

Fundraise & Transaction Update

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce that it has raised funds of £300,000, with £200,000 by way of advance subscription agreements ("Advance Subscriptions") from certain strategic investors,...
RNS 9173894 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.